Landon Capital

Landon capital

Capital Market News, Capital Markets Now

SMXWW

0.145 USD

+ 327.73%
SMX

61.04 USD

+ 250.80%
USARW

2.01 USD

+ 105.10%
MSPRZ

0.0299 USD

+ 96.71%
RELIW

0.0389 USD

+ 93.53%
BTBDW

0.2287 USD

+ 66.81%
CREVW

0.0154 USD

+ 65.59%
KWMWW

0.06 USD

+ 50.00%
KTTAW

0.059 USD

+ 49.37%
ONMDW

0.18 USD

+ 47.54%
VEEE

2.59 USD

+ 45.51%
NUVB+

0.35 USD

+ 45.35%
TMCWW

1.46 USD

+ 43.14%
ABVEW

0.85 USD

+ 41.67%
KTTA

1.46 USD

+ 37.74%
VRCA

9.1 USD

+ 35.62%
APUS

2.92 USD

+ 33.33%
VGASW

0.12 USD

+ 33.33%
DSX+

0.13 USD

+ 32.65%
NCPLW

0.0285 USD

+ 31.34%

Top Gainer

Latest News

What’s your name, Entero Therapeutics (NASDAQ: ENTO) change name to GridAI Entero Therapeutics Inc (NASDAQ: ENTO) stock rose 1.8% in Friday’s premarket trading as the company announced plans to change its name to GridAI Technologies Corp. The rebranding, which takes effect on December 1, 2025, reflects the company’s strategic shift following its acquisition of GRID AI Corp, a grid-edge AI-driven …

FDA approves AstraZeneca’s Imfinzi for early-stage stomach and GEJ cancers AstraZeneca’s (OTC: AZNCF) cancer drug Imfinzi (durvalumab) has been approved in the United States as a treatment for adults with certain types of stomach and gastroesophageal junction (GEJ) cancers that can be surgically removed. The drug is used along with standard chemotherapy before and after surgery, and then by itself …